文献速递胸部肿瘤放疗姑息放疗与转移瘤

大剂量精准靶向放疗联合免疫治疗转移性非小细胞肺癌的2期单臂试验

A Phase 2 Single-Arm Trial of High-Dose Precision Targeted Radiation Therapy Added to Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-09-30

这项2期单臂试验纳入45例已接受抗PD-1/抗PD-L1免疫检查点抑制剂治疗4周以上的转移性非小细胞肺癌患者,给予1至4个颅外肿瘤大剂量放疗并继续免疫治疗。44例可评估患者24周无进展生存率为60%(95%CI 44%-75%),高于历史对照的35%(P<.001),中位无进展生存6.9个月,中位总生存27.4个月。

要点

  • 24周无进展生存率60%(95%CI 44%-75%),高于历史对照35%(P<.001)。
  • 中位无进展生存6.9个月(95%CI 4.0-13.5个月),中位总生存27.4个月(95%CI 20.4个月-未达到)。
  • 局部复发累积发生率1、2、3年均为5%;观察到2例剂量限制性毒性(5%),含1例5级肺炎。

核心结论

  • 该策略较仅接受免疫检查点抑制剂的历史对照改善了24周无进展生存。
  • 出色的局部控制支持大剂量放疗在处理宏观病灶中的疗效。

研究设计与样本

  • 单臂2期试验,2017年7月至2021年5月入组45例已接受抗PD-1/抗PD-L1免疫检查点抑制剂治疗4周以上的转移性非小细胞肺癌患者。
  • 患者接受1至4个颅外肿瘤的大剂量放疗,并继续免疫检查点抑制剂治疗直至进展或不可接受的毒性。
  • 主要终点为24周无进展生存率,与历史对照率35%进行比较。

主要发现

  • 44例可评估患者中位年龄71岁,75%为腺癌,64%为多转移性疾病,已知PD-L1百分比的癌症中85%为PD-L1阳性。
  • 中位治疗肿瘤数为2个,最常见剂量为40 Gy分10次(41/81个肿瘤)。
  • 中位随访23.3个月,24周无进展生存率为60%(95%CI 44%-75%),高于历史对照率35%(P<.001)。
  • 中位无进展生存6.9个月(95%CI 4.0-13.5个月),中位总生存27.4个月(95%CI 20.4个月-未达到)。
  • 部分研究前免疫检查点抑制剂治疗期间疾病进展的患者对研究治疗获得持久缓解,最长达53个月;局部复发累积发生率1、2、3年均为5%。

关键数值与推荐

  • 24周无进展生存率60%(95%CI 44%-75%),历史对照率35%,P<.001。
  • 中位无进展生存6.9个月(95%CI 4.0-13.5个月)。
  • 中位总生存27.4个月(95%CI 20.4个月-未达到)。
  • 局部复发累积发生率1、2、3年均为5%。
  • 剂量限制性毒性2例(5%),包括1例5级肺炎。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: For metastatic non-small cell lung cancer, the addition of radiation therapy (RT) to immune checkpoint inhibitor (ICI) therapy could have synergistic anti-cancer effects and address the most threatening tumors. We posited that the addition of high-dose RT to ICI could prolong progression-free survival (PFS). METHODS AND MATERIALS: In this single-arm phase 2 trial, 45 patients with metastatic non-small cell lung cancer who had received an anti-PD-1/anti-PD-L1 ICI for 4+ weeks were enrolled from July 2017 to May 2021. Patients received high-dose RT to 1 to 4 extracranial tumors and continued ICI until progression or unacceptable toxicity. The primary endpoint was PFS at 24 weeks, comparing with a historical control rate of 35%. RESULTS: Of 44 evaluable patients, median age was 71, 75% had adenocarcinoma, 64% had polymetastatic disease, and 85% of cancers with known PD-L1 percentage were PD-L1-positive. Median number of treated tumors was 2 and most common dose was 40 Gy in 10 fractions (41/81 tumors). Median follow-up was 23.3 months. The trial met the primary outcome: 24-week PFS was 60% (95% CI, 44%-75%), higher than the historical control rate (P < .001). Median PFS was 6.9 months (95% CI, 4.0-13.5 months) and median overall survival was 27.4 months (95% CI, 20.4-not reached). Several patients with prestudy disease progression on ICI treatment achieved durable responses to study treatment, up to 53 months. Local recurrence rate was low: cumulative incidence of 5% at 1, 2, and 3 years. Two dose-limiting toxicities were observed (5%), including 1 grade 5 pneumonitis. CONCLUSIONS: The strategy improved 24-week PFS compared with historical controls receiving ICI alone. The excellent local control supports the efficacy of high-dose RT in addressing macroscopic disease.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Gensheimer MF, Kotha NV, Vitzthum LK, et al. A Phase 2 Single-Arm Trial of High-Dose Precision Targeted Radiation Therapy Added to Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 39357790. doi:10.1016/j.ijrobp.2024.09.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。